Diabetes care products boost Novo Nordisk's sales in 1996
This article was originally published in Clinica
Executive Summary
Danish company Novo Nordisk's healthcare business recorded sales of DKr 11,078 million ($1,696 million), up 12%, in 1996. The healthcare and enzyme company reported 15% sales growth for its diabetes products, to DKr 7,784 million. This growth is due to increased sales of its Penfill for NovoPen injectors and the disposable NovoLet delivery system. Sales in the US and Asia, particularly Japan, were good. Group turnover was up 8% to DKr 14,873 million, and net income rose 15% to DKr 1,799 million.